Literature DB >> 12853976

Lats2, a putative tumor suppressor, inhibits G1/S transition.

Yunfang Li1, Jing Pei, Hong Xia, Hengning Ke, Hongyan Wang, Wufan Tao.   

Abstract

Lats2 is a new member of the Lats tumor suppressor family. The human LATS2 gene is located at chromosome 13q11-12, which has been shown to be a hot spot (67%) for LOH in nonsmall cell lung cancer. In order to understand the function of LATS2 in the control of tumor development, we ectopically expressed mouse Lats2 via retroviral infection in NIH3T3/v-ras cells to examine whether Lats2 plays a role in suppressing tumor development and regulating cell proliferation. We have found that ectopic expression of Lats2 in NIH3T3/v-ras cells suppresses development of tumors in athymic nude mice and inhibits proliferation of NIH3T3/v-ras cells in an in vitro assay. Cell cycle profile analysis demonstrated that ectopic expression of Lats2 inhibited the G1/S transition. Further mechanistic studies revealed that cyclin E/CDK2 kinase activity was downregulated in Lats2-transduced NIH3T3/v-ras cells, while other cell cycle regulators controlling the G1/S transition were not affected. We have also shown that LATS2 kinase activity and two LATS conserved domains (LCDs) are required for Lats2 to suppress tumorigenicity and to inhibit cell growth. In addition, the LATS2 protein is cytoplasmic during interphase in NIH3T3 cells, while it becomes localized to the mitotic apparatus during mitosis. Finally, we propose a model in which a combination of mammalian Lats2 and Lats1 control cell proliferation by negatively regulating different cell cycle check points.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853976     DOI: 10.1038/sj.onc.1206603

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  80 in total

1.  Down-regulation of LATS2 in non-small cell lung cancer promoted the growth and motility of cancer cells.

Authors:  Feng Yao; Hongcheng Liu; Zhigang Li; Chenxi Zhong; Wentao Fang
Journal:  Tumour Biol       Date:  2014-11-13

2.  Transcriptional analysis of pluripotency reveals the Hippo pathway as a barrier to reprogramming.

Authors:  Han Qin; Kathryn Blaschke; Grace Wei; Yuki Ohi; Laure Blouin; Zhongxia Qi; Jingwei Yu; Ru-Fang Yeh; Matthias Hebrok; Miguel Ramalho-Santos
Journal:  Hum Mol Genet       Date:  2012-01-27       Impact factor: 6.150

3.  Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors.

Authors:  Marco Ragusa; Luisa Statello; Marco Maugeri; Alessandra Majorana; Davide Barbagallo; Loredana Salito; Mariangela Sammito; Manuela Santonocito; Rosario Angelica; Andrea Cavallaro; Marina Scalia; Rosario Caltabiano; Giuseppe Privitera; Antonio Biondi; Maria Di Vita; Alessandro Cappellani; Enrico Vasquez; Salvatore Lanzafame; Elisabetta Tendi; Salvatore Celeste; Cinzia Di Pietro; Francesco Basile; Michele Purrello
Journal:  J Mol Med (Berl)       Date:  2012-06-04       Impact factor: 4.599

Review 4.  Recent Advances of the Hippo/YAP Signaling Pathway in Brain Development and Glioma.

Authors:  Taohui Ouyang; Wei Meng; Meihua Li; Tao Hong; Na Zhang
Journal:  Cell Mol Neurobiol       Date:  2019-11-25       Impact factor: 5.046

5.  Stability of the LATS2 tumor suppressor gene is regulated by tristetraprolin.

Authors:  Hyun Hee Lee; Mai-Tram Vo; Hyo Jeong Kim; Unn Hwa Lee; Chae Won Kim; Hong Kyeung Kim; Myoung Seok Ko; Won Hyuck Lee; Seung Joo Cha; Young Joo Min; Dae Hwa Choi; Ho Seok Suh; Byung Ju Lee; Jeong Woo Park; Wha Ja Cho
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

6.  A kinase shRNA screen links LATS2 and the pRB tumor suppressor.

Authors:  Katrin Tschöp; Andrew R Conery; Larisa Litovchick; James A Decaprio; Jeffrey Settleman; Ed Harlow; Nicholas Dyson
Journal:  Genes Dev       Date:  2011-04-15       Impact factor: 11.361

7.  Genome-wide impact of a recently expanded microRNA cluster in mouse.

Authors:  Grace X Y Zheng; Arvind Ravi; Genevieve M Gould; Christopher B Burge; Phillip A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-12       Impact factor: 11.205

8.  Contribution of LATS1 and LATS2 promoter methylation in OSCC development.

Authors:  Mohammad Ayoub Rigi Ladiz; Maryam Najafi; Dor Mohammad Kordi-Tamandani
Journal:  J Cell Commun Signal       Date:  2016-10-19       Impact factor: 5.782

9.  Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.

Authors:  Y Aylon; N Yabuta; H Besserglick; Y Buganim; V Rotter; H Nojima; M Oren
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

10.  The p53 Pathway Encounters the MicroRNA World.

Authors:  Apana Takwi; Yong Li
Journal:  Curr Genomics       Date:  2009-05       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.